表紙
市場調查報告書

再生醫療的全球市場:2020年∼2024年

Regenerative Medicine Market by Technology and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 321466
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
再生醫療的全球市場:2020年∼2024年 Regenerative Medicine Market by Technology and Geography - Forecast and Analysis 2020-2024
出版日期: 2020年02月04日內容資訊: 英文 120 Pages
簡介

全球再生醫療市場在2020年∼2024年的預測期間內,預計將以20%的年複合成長率增長,達到95億5,000萬美元的規模。市場成長主要因素是慢性疾病的盛行率增加。此外,臨床試驗的增長有望推動市場增長。

本報告提供全球再生醫療市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

  • 市場概況

市場情形

  • 市場生態系統
  • 價值鏈分析

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2019年
  • 市場預測:2019-2024年的預測

波特的五力分析

  • 波特的五力分析摘要
  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 對手的威脅
  • 市場情況

市場區隔:各技術

  • 市場區隔
  • 比較:各技術市場規模與預測2019-2024
  • 以細胞及組織為主
  • 基因治療
  • 市場機會:各技術

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模與預測2019-2024
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會:各地區

成長要素,課題,及趨勢

  • 市場成長要素
  • 數量的成長要素-需求主導型成長
  • 數量的成長要素-供給主導型成長
  • 數量的成長要素-外部要素
  • 數量的成長要素-需求轉移到鄰近市場
  • 價格上升要素-通貨膨脹
  • 價格上升要素-從低價格單位轉變到高價格單位
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 業者情勢
  • 形勢的創新

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Allergan Plc
  • Amgen Inc.
  • 日立化成
  • Integra LifeSciences Holdings Corp.
  • Medtronic Plc
  • MiMedx Group Inc.
  • Organogenesis Holdings Inc.
  • Smith & Nephew Plc
  • 武田藥品工業
  • Zimmer Biomet Holdings Inc.

附錄

  • 調查範圍
  • 美金的貨幣換算比率
  • 調查方法
  • 簡稱的清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR41171

Technavio has been monitoring the global regenerative medicine market and it is poised to grow by USD 9.55 bn during 2020-2024, progressing at a CAGR of 20% during the forecast period. Our reports on global regenerative medicine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic diseases.

In addition, increasing number of clinical trials is anticipated to boost the growth of the global regenerative medicine market as well.

Market Segmentation

Technavio's global regenerative medicine market is segmented as below:

Technology

  • Cell and tissue-based
  • Gene therapy

Geographic segmentation

  • North America
  • Europe
  • Asia
  • ROW

Key Trends for global regenerative medicine market growth

This study identifies increasing number of clinical trials as the prime reasons driving the global regenerative medicine market growth during the next few years.

Prominent vendors in global regenerative medicine market

We provide a detailed analysis of around 25 vendors operating in the global regenerative medicine market, including some of the vendors such as Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd. and Zimmer Biomet Holdings Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavi's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Technology

  • Market segments
  • Comparison by Technology placement
  • Cell and tissue-based - Market size and forecast 2019-2024
  • Gene therapy - Market size and forecast 2019-2024
  • Market opportunity by Technology

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Allergan Plc
  • Amgen Inc.
  • Hitachi Chemical Co. Ltd.
  • Integra LifeSciences Holdings Corp.
  • Medtronic Plc
  • MiMedx Group Inc.
  • Organogenesis Holdings Inc.
  • Smith & Nephew Plc
  • Takeda Pharmaceutical Co. Ltd.
  • Zimmer Biomet Holdings Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ million)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Technology placement - Market share 2019-2024 (%)
  • 23.Comparison by Technology placement
  • 24.Cell and tissue-based - Market size and forecast 2019-2024 ($ million)
  • 25.Cell and tissue-based - Year-over-year growth 2019-2024 (%)
  • 26.Gene therapy - Market size and forecast 2019-2024 ($ million)
  • 27.Gene therapy - Year-over-year growth 2019-2024 (%)
  • 28. Market opportunity by Technology
  • 29.Customer landscape
  • 30.Market share by geography 2019-2024 (%)
  • 31.Geographic comparison
  • 32.North America - Market size and forecast 2019-2024 ($ million)
  • 33.North America - Year-over-year growth 2019-2024 (%)
  • 34.Europe - Market size and forecast 2019-2024 ($ million)
  • 35.Europe - Year-over-year growth 2019-2024 (%)
  • 36.Asia - Market size and forecast 2019-2024 ($ million)
  • 37.Asia - Year-over-year growth 2019-2024 (%)
  • 38.ROW - Market size and forecast 2019-2024 ($ million)
  • 39.ROW - Year-over-year growth 2019-2024 (%)
  • 40.Key leading countries
  • 41.Market opportunity by geography ($ million)
  • 42.Impact of drivers
  • 43.Impact of challenges
  • 44.Landscape disruption
  • 45.Industry risks
  • 46.Vendors covered
  • 47.Market positioning of vendors
  • 48.Allergan Plc - Overview (1/3)
  • 49.Allergan Plc - Overview (2/3)
  • 50.Allergan Plc - Overview (3/3)
  • 51.Allergan Plc - Business segments
  • 52.Allergan Plc - Key offerings
  • 53.Allergan Plc - Key customers
  • 54.Allergan Plc - Segment focus
  • 55.Amgen Inc. - Overview (1/3)
  • 56.Amgen Inc. - Overview (2/3)
  • 57.Amgen Inc. - Overview (3/3)
  • 58.Amgen Inc. - Business segments
  • 59.Amgen Inc. - Key offerings
  • 60.Amgen Inc. - Key customers
  • 61.Amgen Inc. - Segment focus
  • 62.Hitachi Chemical Co. Ltd. - Overview (1/3)
  • 63.Hitachi Chemical Co. Ltd. - Overview (2/3)
  • 64.Hitachi Chemical Co. Ltd. - Overview (3/3)
  • 65.Hitachi Chemical Co. Ltd. - Business segments
  • 66.Hitachi Chemical Co. Ltd. - Key offerings
  • 67.Hitachi Chemical Co. Ltd. - Key customers
  • 68.Hitachi Chemical Co. Ltd. - Segment focus
  • 69.Integra LifeSciences Holdings Corp. - Overview (1/3)
  • 70.Integra LifeSciences Holdings Corp. - Overview (2/3)
  • 71.Integra LifeSciences Holdings Corp. - Overview (3/3)
  • 72.Integra LifeSciences Holdings Corp. - Business segments
  • 73.Integra LifeSciences Holdings Corp. - Key offerings
  • 74.Integra LifeSciences Holdings Corp. - Key customers
  • 75.Integra LifeSciences Holdings Corp. - Segment focus
  • 76.Medtronic Plc - Overview (1/3)
  • 77.Medtronic Plc - Overview (2/3)
  • 78.Medtronic Plc - Overview (3/3)
  • 79.Medtronic Plc - Business segments
  • 80.Medtronic Plc - Key offerings
  • 81.Medtronic Plc - Key customers
  • 82.Medtronic Plc - Segment focus
  • 83.MiMedx Group Inc. - Overview (1/3)
  • 84.MiMedx Group Inc. - Overview (2/3)
  • 85.MiMedx Group Inc. - Overview (3/3)
  • 86.MiMedx Group Inc. - Product and service
  • 87.MiMedx Group Inc. - Key offerings
  • 88.MiMedx Group Inc. - Key customers
  • 89.MiMedx Group Inc. - Segment focus
  • 90.Organogenesis Holdings Inc. - Overview (1/3)
  • 91.Organogenesis Holdings Inc. - Overview (2/3)
  • 92.Organogenesis Holdings Inc. - Overview (3/3)
  • 93.Organogenesis Holdings Inc. - Business segments
  • 94.Organogenesis Holdings Inc. - Key offerings
  • 95.Organogenesis Holdings Inc. - Key customers
  • 96.Organogenesis Holdings Inc. - Segment focus
  • 97.Smith & Nephew Plc - Overview (1/3)
  • 98.Smith & Nephew Plc - Overview (2/3)
  • 99.Smith & Nephew Plc - Overview (3/3)
  • 100.Smith & Nephew Plc - Business segments
  • 101.Smith & Nephew Plc - Key offerings
  • 102.Smith & Nephew Plc - Key customers
  • 103.Smith & Nephew Plc - Segment focus
  • 104.Takeda Pharmaceutical Co. Ltd. - Overview (1/3)
  • 105.Takeda Pharmaceutical Co. Ltd. - Overview (2/3)
  • 106.Takeda Pharmaceutical Co. Ltd. - Overview (3/3)
  • 107.Takeda Pharmaceutical Co. Ltd. - Business segments
  • 108.Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 109.Takeda Pharmaceutical Co. Ltd. - Key customers
  • 110.Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 111.Zimmer Biomet Holdings Inc. - Overview (1/3)
  • 112.Zimmer Biomet Holdings Inc. - Overview (2/3)
  • 113.Zimmer Biomet Holdings Inc. - Overview (3/3)
  • 114.Zimmer Biomet Holdings Inc. - Product and service
  • 115.Zimmer Biomet Holdings Inc. - Key offerings
  • 116.Zimmer Biomet Holdings Inc. - Key customers
  • 117.Zimmer Biomet Holdings Inc. - Segment focus
  • 118.Currency conversion rates for US$
  • 119.Research Methodology
  • 120.Validation techniques employed for market sizing
  • 121.Information sources
  • 122.List of abbreviations
Back to Top